Big pharma braces for revenue headwinds as patent expiries loom - Pharmaceutical Technology

Big pharma braces for revenue headwinds as patent expiries loom - Pharmaceutical Technology

More than half of the top 15 pharma companies are expected to face challenges in managing the patent cliff.

Big Pharma prepare for next patent cliff as blockbuster drugs revenue losses loom, says GlobalData

The pharmaceutical industry is bracing for one of its most financially significant patent cliffs in over a decade, with multiple blockbuster drugs set to lose exclusivity by 2030. As biosimilars and generics flood the market, pricing pressures will intensify—particularly in oncology—challenging pharma companies to rethink revenue strategies, pipeline investments, and lifecycle management to safeguard long-term growth, says GlobalData, a leading …